Varda Space Industries has raised approximately $251 million in a new funding round, giving the space manufacturing company a valuation of about $1.6 billion as it works to develop a new way of producing pharmaceutical materials in orbit.
The California-based company is focused on using microgravity as a manufacturing environment. Instead of bringing manufacturing processes entirely back to Earth, Varda sends materials into orbit, processes them inside specialized spacecraft and then returns the finished material to Earth.
The concept could eventually create a new category of space-based manufacturing, particularly for pharmaceuticals and other high-value materials.
Varda Raises $251 Million
Varda announced a $251 million Series D financing round on September 30, 2026. Reuters reported that the funding gives the company a valuation of approximately $1.6 billion.
The latest financing brings Varda's total capital raised to roughly $598 million.
The company was founded in 2021 by Will Bruey, a former SpaceX engineer, and Delian Asparouhov of Founders Fund.
Varda's objective is to develop repeatable infrastructure for manufacturing materials in space and returning them safely to Earth.
Why Make Medicines in Space?
Microgravity can change how certain materials behave during manufacturing.
On Earth, gravity influences the way crystals form, fluids move and different materials interact. In orbit, many of those effects are dramatically reduced.
Scientists have therefore been studying whether microgravity can produce pharmaceutical crystals or other biological materials with characteristics that are difficult to achieve using conventional manufacturing techniques.
Varda is attempting to turn that scientific possibility into a commercial manufacturing system.
Varda Uses Reusable Orbital Capsules
The company's approach is based on autonomous spacecraft designed to travel into orbit, process materials and return them to Earth.
Varda describes its platform as a microgravity-enabled life-sciences system that processes materials in orbit and brings them back to Earth.
The company's W-Series vehicles are designed around this concept.
Rather than requiring astronauts to operate a factory in space, Varda's spacecraft are designed to conduct manufacturing operations autonomously.
Space Manufacturing Is Moving Beyond Experiments
For decades, researchers have used the International Space Station and other spacecraft to investigate how materials behave in microgravity.
However, space-based manufacturing has historically remained limited by launch costs, spacecraft availability and the difficulty of safely returning products to Earth.
Varda is attempting to address those problems by developing a dedicated commercial platform that can fly repeatedly.
The company believes frequent launches and autonomous reentry could eventually make orbital manufacturing a practical part of the global supply chain.
Six Missions Have Already Flown
According to Reuters, Varda has conducted six missions since 2023.
The company has used those missions to develop and test its spacecraft, manufacturing systems and reentry technology.
Varda's own company information also shows that its missions are being used for pharmaceutical research as well as other commercial and government payloads.
Its W-6 mission, for example, successfully returned to Earth in 2026 after carrying payloads associated with NASA and other government partners.
Varda Wants Pharmaceuticals Made in Orbit
One of Varda's major long-term goals is to produce pharmaceuticals in space and eventually return those products to patients on Earth.
The company has already been working with pharmaceutical and biotechnology organizations to investigate potential applications of microgravity.
In May 2026, Varda announced a collaboration with United Therapeutics to explore microgravity-enabled treatments related to rare pulmonary disease.
The company's stated ambition is to eventually produce pharmaceutical products in space that can be used on Earth.
Why the Pharmaceutical Industry Is Interested
Drug development often depends on precisely controlling the structure of molecules and crystals.
Some pharmaceutical compounds can form different crystal structures, and those structures can influence characteristics such as stability, solubility and processing.
Researchers are investigating whether microgravity can provide a useful environment for producing certain structures.
However, this remains an area of scientific and commercial development. Space-based production does not automatically mean that every medicine will be better or cheaper.
Government Business Is Still Important
Varda's business is not currently limited to pharmaceuticals.
Reuters reported that approximately 70% of the company's customer base is government-focused.
The company's spacecraft can also be used for technology demonstrations, hypersonic research and other payloads.
This government business provides another application for the company's spacecraft while its commercial pharmaceutical activities continue to develop.
Two Capsules Are Planned for a New Mission
Varda is also preparing for a new milestone in its flight program.
According to Reuters, the company plans to launch two capsules simultaneously on Thursday. The spacecraft will carry hypersonic research payloads for the Pentagon as well as commercial customers.
Operating multiple spacecraft is an important step toward the company's goal of creating a higher-frequency orbital manufacturing business.
Varda Is Preparing for More Launches
The company has also secured launch bookings that extend through 2029.
Reuters reported that Varda has 28 launch bookings through that year, providing a significant pipeline for future missions.
A regular launch schedule is important to Varda's business model because the company wants space manufacturing to operate more like an industrial process rather than a rare scientific experiment.
Competition Is Growing
Varda is entering an emerging market that is attracting interest from other space companies.
Companies are exploring orbital manufacturing, spacecraft-based research and commercial reentry services as launch costs decline and access to low Earth orbit expands.
Varda also faces competition in orbital cargo and reentry services from companies developing alternative spacecraft and transportation systems.
The growth of this market could eventually create multiple specialized services for manufacturing, research and transportation in space.
The Space Economy Is Expanding
Varda's latest funding round comes at a time when the space industry is expanding beyond traditional satellite launches.
Commercial companies are increasingly developing spacecraft for scientific research, communications, Earth observation, defense applications and manufacturing.
Space-based production represents another potential market in this broader space economy.
If companies can demonstrate that certain products can be manufactured more efficiently or with useful properties in microgravity, orbital manufacturing could become a new category of commercial activity.
What Happens Next?
Varda's immediate focus is expected to remain on increasing the frequency of its missions, improving its spacecraft and developing commercial pharmaceutical applications.
The company will need to demonstrate that products manufactured in orbit can move from experimental research into reliable commercial production.
It will also need to establish a repeatable launch-and-reentry system that can operate at a scale large enough to support commercial customers.
For pharmaceutical applications, additional scientific research and regulatory work will also be necessary before space-manufactured products can become widely available to patients.
A Factory Above Earth?
Varda's business represents one of the more unusual directions in the rapidly developing commercial space industry.
Instead of using space simply as a destination for satellites or astronauts, the company is attempting to use orbit as a place where valuable products can actually be manufactured.
The $251 million funding round gives Varda additional capital to develop that vision and expand its spacecraft operations.
Conclusion
Varda Space's $251 million Series D financing puts a new spotlight on the emerging idea of manufacturing medicines in orbit.
With a reported valuation of approximately $1.6 billion, the company is now preparing to scale its spacecraft operations while continuing pharmaceutical research in microgravity.
The technology remains under development, and it is still too early to know which products will ultimately be commercially successful. But Varda's growing flight schedule, pharmaceutical partnerships and new funding demonstrate that space manufacturing is moving from laboratory research toward a potential commercial industry.
If the company succeeds in creating a reliable system for producing and returning high-value pharmaceutical materials from orbit, the space economy could eventually include not only satellites and spacecraft—but factories operating hundreds of kilometres above Earth.
Journalist: Vijay Singh